News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Private UK Biotech Pharminox Signs $40 Million Drug Development Deal With Schering-Plough Research Institute (SGP)



12/11/2006 12:55:15 PM

Nottingham, UK, 11 December 2006 - Pharminox Limited, ("Pharminox" or "the Company") the private UK oncology R&D company, today announced that it has signed an agreement with the Schering-Plough Research Institute, the research arm of Schering-Plough Corporation (“Schering-Plough”), to undertake a joint research programme aimed at discovering novel small molecule anti-cancer therapies.

Under the terms of the agreement, Schering-Plough will provide funding to Pharminox for up to two years to carry out a focused medicinal chemistry programme to synthesise novel anti-cancer agents, which will be screened for anti-tumour activity at Schering-Plough’s laboratories in Kenilworth, New Jersey. Schering-Plough will have an option to license intellectual property arising from the programme, including potential clinical development candidates.

If Schering-Plough exercises its option it will take over full responsibility for the development and commercialisation of clinical development candidates arising from the collaboration, and Pharminox will be eligible to receive a series of pre-approval milestone payments as well as royalties on sales of commercialised products. Research funding and potential milestone payments to Pharminox under the collaboration could exceed $40 million, excluding royalties. Detailed financial terms of the agreement were not disclosed.

The Pharminox discovery team will be led by Professor Malcolm Stevens OBE, Chief Scientific Officer of Pharminox. Until September 2006, Professor Stevens was also Director of the Cancer Research UK Experimental Cancer Chemotherapy Group, latterly based at the University of Nottingham. In this role he was responsible for the discovery and early development of temozolomide, the market-leading treatment for malignant glioma, a common form of brain tumour. Temozolomide is licensed to and marketed by Schering-Plough globally.

Commenting on today’s announcement, Peter Worrall, Chief Executive of Pharminox said, “We are very pleased to be collaborating with Schering-Plough on this exciting new programme. As our first deal with a major pharmaceutical company it represents an important validation of Pharminox’s credentials in the field of cancer research, and reflects the high regard that Schering-Plough has for Professor Stevens and his team as a result of their earlier, highly successful collaboration on temozolomide.”

Malcolm Stevens added, “I am delighted to be renewing my acquaintance with Schering-Plough and we look forward to working closely with the Schering-Plough team.”

ENDS

Enquiries:

Pharminox

Peter Worrall, Chief Executive Tel: +44 (0)1428 645416 / +44 (0)7887 682669

Citigate Dewe Rogerson

Mark Swallow PhD Tel: +44 (0)20 7282 2948 / +44 (0)7903 737703

NOTES TO EDITORS

About Pharminox Ltd

Pharminox (www.pharminox.com) is an emerging UK biopharmaceutical company focused on the discovery and development of small molecule drugs for the treatment of cancer. It was formed in late 2001 as a spin-out from Oxford University with backing from IP Group plc, but has subsequently moved its discovery research activities to Nottingham. It owns or has acquired the rights to a number of novel programmes from the laboratories of Professor Malcolm Stevens OBE, formerly Director of the Cancer Research UK Experimental Cancer Chemotherapy Group, and is currently seeking further funding to progress these programmes into development.

Malcolm Stevens, who joined Pharminox in 2004 as Chief Scientific Officer, has had a long and distinguished career in cancer research. In addition to the discovery and early development of temozolomide (Temodaltm / Temodartm), now marketed by Schering-Plough, he has been responsible for the discovery of five other new chemical entities that have progressed into clinical trials, including one other marketed product, bropirimine, which has received regulatory approval in Japan for the treatment of prostate cancer.

Mark Swallow, Ph.D. Citigate Dewe Rogerson

+44 (0)20 7282 2948 (direct) +44 (0)7903 737703 (mobile) +44 (0)20 7638 9571 (switchboard) +44 (0)20 7282 2811 (fax)

3 London Wall Buildings London Wall London EC2M 5SY UK


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES